Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|
Free Cash Flow | $0.0 | ($124.6M) | ($148.8M) | ($301.8M) | ($112.9M) | $870.2M | $13.9B | $5,045.6M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, BioNTech SE's last 12-month Free Cash Flow is $1,069.0M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, BioNTech SE's Free Cash Flow growth was (78.6%). The average annual Free Cash Flow growth rates for BioNTech SE have been N/A over the past three years, N/A over the past five years.
Over the last year, BioNTech SE's Free Cash Flow growth was (78.6%), which is lower than industry growth of (0.1%). It indicates that BioNTech SE's Free Cash Flow growth is Bad.